Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 known ✓ | Q92769 | 2/20 | 0.55 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 2/20 | 0.55 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 2/20 | 0.55 |
| ▸ | HDAC1 known ✓ | Q13547 | 3/20 | 0.54 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.54 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.54 |
| ▸ | HDAC4 known ✓ | P56524 | 1/20 | 0.54 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.54 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 1/20 | 0.54 |
| ▸ | HDAC10 known ✓ | Q969S8 | 1/20 | 0.54 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 1/20 | 0.54 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 1/20 | 0.54 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 1/20 | 0.54 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.52 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.64 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6952080 | 1.00 | KEAP1 (0.64) | KEAP1FFAR1ALDH1A1PRMT1HDAC2 | |
| SCHEMBL2593 | 0.98 | KEAP1 (0.67) | KEAP1FFAR1ALDH1A1PRMT1HDAC2 | |
| Hydrazine SCHEMBL28262207 | 0.95 | KEAP1 (0.64) | KEAP1FFAR1ALDH1A1PRMT1HDAC2 | |
| Fluoride SCHEMBL27900680 | 0.95 | KEAP1 (0.64) | KEAP1FFAR1ALDH1A1PRMT1HDAC2 | |
| Bicarbonate SCHEMBL28311766 | 0.95 | KEAP1 (0.64) | KEAP1FFAR1ALDH1A1PRMT1HDAC2 | |
| Ammonia Solution, Strong SCHEMBL10416110 | 0.95 | KEAP1 (0.64) | KEAP1FFAR1ALDH1A1PRMT1HDAC2 | |
| Oxalic Acid SCHEMBL27523006 | 0.93 | KEAP1 (0.61) | KEAP1FFAR1ALDH1A1PRMT1HDAC2 | |
| SCHEMBL5020712 | 0.93 | FFAR1 (0.69) | KEAP1FFAR1ALDH1A1PRMT1HDAC2 | |
| SCHEMBL5047112 | 0.90 | HDAC1 (0.62) | KEAP1FFAR1ALDH1A1PRMT1HDAC2 | |
| Formic Acid SCHEMBL30781911 | 0.90 | KEAP1 (0.57) | KEAP1FFAR1ALDH1A1PRMT1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250228242-A1 | PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2025-07-17 | — | — | US | claimed |
| EP-1751095-B1 | SUBSTITUTED CYCLOHEXYLCARBOXYLIC ACID DERIVATIVES | GRUENENTHAL GMBH (DE) | 2014-06-18 | — | — | EP | claimed |
| CN-101139383-B | C end modification endomorphin 2 | UNIV LANZHOU | 2011-09-07 | — | — | CN | claimed |
| CN-100378126-C | C-terminally modified endomorphin1 | UNIV LANZHOU (CN) | 2008-04-02 | — | — | CN | claimed |
| EP-1897881-A2 | Compounds useful for the treatment of obesity, type II diabetes and CNS disorders | Biovitrum AB (publ) (SE) | 2008-03-12 | — | — | EP | claimed |
| CN-101139383-A | C end modification endomorphin 2 | UNIV LANZHOU (CN) | 2008-03-12 | — | — | CN | claimed |
| CN-100363380-C | Liquid phase synthetic method for endomorphine -1 and endomorphine -2 | UNIV LANZHOU (CN) | 2008-01-23 | — | — | CN | claimed |
| US-7241802-B2 | Substituted cyclohexylcarboxylic acid amide compounds | GRUENENTHAL GMBH (DE) | 2007-07-10 | — | — | US | claimed |
| US-20070105941-A1 | Substituted cyclohexylcarboxylic acid amide compounds | GRUENENTHAL GMBH (DE) | 2007-05-10 | — | — | US | claimed |
| CN-1754890-A | C-terminal modified endomorphin 1, endomorphin 2 | UNIV LANZHOU (CN) | 2006-04-05 | — | — | CN | claimed |
| CN-1715295-A | Liquid phase synthetic method for endomorphine -1 and endomorphine -2 | UNIV LANZHOU (CN) | 2006-01-04 | — | — | CN | claimed |
| EP-1513828-A1 | NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS | Biovitrum AB (SE) | 2005-03-16 | — | — | EP | claimed |
| US-20040024210-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-05 | — | — | US | claimed |
| WO-2004000828-A1 | NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS | BIOVITRUM AB (SE) | 2003-12-31 | — | — | WO | claimed |
| US-20250228242-A1 | PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2025-07-17 | — | — | US | disclosed |
| US-12340996-B2 | Method for rapid on-site detection of fentanyl analogs using a miniature mass spectrometer | CHINESE ACADEMY OF INSPECTION AND QUARANTINE (CN) | 2025-06-24 | — | — | US | disclosed |
| EP-4305021-A1 | USP30 INHIBITORS AND USES THEREOF | Vincere Biosciences, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20040024210-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-05 | — | — | US | disclosed |
| WO-2004000828-A1 | NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS | BIOVITRUM AB (SE) | 2003-12-31 | — | — | WO | disclosed |
| CN-1335841-A | N- (iminomethyl) amine derivatives, their preparation, their use as medicaments and pharmaceutical compositions containing them | SOD CONSEILS RECH APPLIC (FR) | 2002-02-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024210-A1 | New compounds | SULT1E1, SULT2A1, SULT1A1 | HDAC2 619/4885HDAC8 1976/4885HDAC6 752/4885 |
| US-20070105941-A1 | Substituted cyclohexylcarboxylic acid amide compounds | OPRL1, OPRK1, HCAR1 | HDAC2 1446/4885HDAC8 1545/4885HDAC6 1442/4885 |
| US-20250228242-A1 | PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL | APP, APBA1, PRNP | HDAC2 4296/4885HDAC8 4497/4885HDAC6 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.